ohm, do you have any references for blood/brain barrier?
My limited reading on antibodies crossing the blood brain barrier is that they don't cross the blood/brain barrier.
Do you have any references that you can share?
I have some doubts as to the basic blood/barrier claims made in today's conference call.
How exactly did they determine that receptor occupancy was 70% inside the monkey brains?
And what cells inside the monkey brain did they test and how did they get them? Are there even enough T-cells present in the CNS to obtain a decent sample?
So I wonder exactly which cells they measured and how did they obtain the cells.
I haven't read much about monoclonal antibodies crossing the blood/brain barrier, but I am familiar with a failed effort by AbbVie and Voyager to deploy monoclonal antibodies to the CNS. About three years ago, AbbVie gave Voyager $150 million upfront to develop monoclonal gene therapy for CNS applications. Voyager, who is experienced in Parkinson's gene therapy delivered directly to the brain, was tasked with developing an AAV viral vector that could deliver a DNA payload. The DNA payload was supposed to form an episome in brain cell nuclei and the express mRNA which would produce monoclonal antibodies.
The AbbVie/Voyager program was a failure because the Voyager AAV viral delivery vector could not be developed.
While the program was a failure, it was illustrative of conventional wisdom on monoclonal antibodies, namely that mabs cannot cross the blood/brain barrier. AbbVie has a big monoclonal antibody business. It seems to me that if AbbVie mabs can cross the blood/brain barrier then no need for the Voyager program.
I have read elsewhere that mabs can't cross the blood brain barrier.
A simple google scholar search "monoclonal antibodies that can cross the blood brain barrier" yields many articles, but they are all tricks to get stuff across. No regular mabs going across.
My limited reading on antibodies crossing the blood brain barrier is that they don't cross the blood/brain barrier.
Do you have any references that you can share?
I have some doubts as to the basic blood/barrier claims made in today's conference call.
How exactly did they determine that receptor occupancy was 70% inside the monkey brains?
And what cells inside the monkey brain did they test and how did they get them? Are there even enough T-cells present in the CNS to obtain a decent sample?
So I wonder exactly which cells they measured and how did they obtain the cells.
I haven't read much about monoclonal antibodies crossing the blood/brain barrier, but I am familiar with a failed effort by AbbVie and Voyager to deploy monoclonal antibodies to the CNS. About three years ago, AbbVie gave Voyager $150 million upfront to develop monoclonal gene therapy for CNS applications. Voyager, who is experienced in Parkinson's gene therapy delivered directly to the brain, was tasked with developing an AAV viral vector that could deliver a DNA payload. The DNA payload was supposed to form an episome in brain cell nuclei and the express mRNA which would produce monoclonal antibodies.
The AbbVie/Voyager program was a failure because the Voyager AAV viral delivery vector could not be developed.
While the program was a failure, it was illustrative of conventional wisdom on monoclonal antibodies, namely that mabs cannot cross the blood/brain barrier. AbbVie has a big monoclonal antibody business. It seems to me that if AbbVie mabs can cross the blood/brain barrier then no need for the Voyager program.
I have read elsewhere that mabs can't cross the blood brain barrier.
A simple google scholar search "monoclonal antibodies that can cross the blood brain barrier" yields many articles, but they are all tricks to get stuff across. No regular mabs going across.
1
